Table 2.
Overall survival estimated by univariate analysis
| Variable | HR (CI) | P value |
|---|---|---|
| Sex (M/F) | 1.10 (0.41–1.31) | ns |
| Age (over 50 years) | 2.09 (0.75–6.75) | ns |
| Disease (paraganglioma/pheochromocytoma) | 0.92 (0.29–2.56) | ns |
| Initial diagnosis (benign/malignant pheochromocytoma) | 0.53 (0.15–2.50) | ns |
| Hypertension | 2.93 (1.02–10.50) | 0.044 |
| Diabetes mellitus | 1.87 (0.52–5.41) | ns |
| Palpitations | 0.94 (0.29–2.62) | ns |
| Symptoms of bone metastases | 3.54 (1.18–13.04) | 0.023 |
| Number of 131I-MIBG therapy (single/multiple 131I-MIBG therapy) |
3.22 (1.21–8.79) | 0.020 |
| Initial responses | ||
| Hormonal response (PD/non-PD) | 3.20 (1.09–9.93) | 0.034 |
| Subjective response (PD/non-PD) | 2.31 (0.82–7.06) | ns |
| Scintigraphic response (PD/non-PD) | 2.28 (0.51–7.33) | ns |
| Objective response (PD/non-PD) | 11.89 (2.14–65.85) | 0.0068 |
HR hazard ratio, CI 95 % confidence interval, ns not significant